Summary of some of the presentations from the session “ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension”
| Study name [ref.] | Population | Intervention | Comparison | Primary/secondary outcomes |
| Exploring efficacy and safety of oral pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) [26] | Progressive fibrosing ILD | Pirfenidone 24 weeks | Placebo | Stopped due to low recruitment; lower FVC decline in treatment arm when applying pre-specified imputation, but not without |
| Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD [3] | Progressive fibrosing unclassifiable ILD | Pirfenidone 24 weeks | Placebo | Primary end-point (FVC change by home spirometry) was not assessed due to technical problems; lower FVC decrease in treatment arm in site spirometry |
| Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial [25] | Progressive fibrosing ILD | Nintedanib 52 weeks | Placebo | Lower adjusted annual rate of decline in FVC (mL·year−1) |
| Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc) [27] | Systemic sclerosis | Tocilizumab 48 weeks | Placebo | No difference in change in modified Rodnan skin score; lower proportion of patients losing >10% of FVC on the treatment arm |
| Transbronchial lung cryobiopsy for interstitial lung disease diagnosis: results of the COLDICE Study [28] | ILD requiring biopsy | Transbronchial lung cryobiopsy | Surgical lung biopsy | High level of agreement between both types of biopsy |
IPF: idiopathic pulmonary fibrosis; ILD: interstitial lung disease; FVC: forced vital capacity.